Shares of MEI Pharma Inc. (MEIP) are soaring over 77% in pre-market today, the company entered into a global license, development and commercialization agreement with Kyowa Kirin Co. Ltd. to further develop and commercialize MEI's ME-401, an oral, once-daily, investigational drug-candidate, selective for phosphatidylinositol 3-kinase delta, in clinical development for the treatment of B-cell malignancies.
from RTT - Before the Bell https://ift.tt/3eviTqa
via IFTTT
No comments:
Post a Comment